Earnings Insights · NVO · Q3 FY2026

Novo Q3 2026 Earnings: GLP-1 Volumes Recover as Guidance Rises Again

By AlgovestIQ ResearchPublished

Share

Key earnings findings

Novo Nordisk A/S (NVO) Q3 FY2026 · results discussed on the earnings call

  1. Novo Nordisk A/S reported Q3 FY2026 revenue of $11.90B against the $11.07B analyst estimate, a 7.5% beat, and EPS of $0.89 against the $0.73 analyst estimate, a 21.8% beat.
  2. NVO closed at $42.18 on Nov 4, 2026, up 5.0% from $40.19 on Nov 3, 2026, the last close before the results were released.
  3. Novo reported DKK 79.2B in Q3 adjusted sales, up 4% at constant exchange rates, as growth returned across both U.S. and International Operations.

Sources: the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references

Did Novo Nordisk A/S beat earnings expectations?

Actual
Estimate
Surprise
Revenue
$11.90B
$11.07B
+7.5%
EPS
$0.89
$0.73
+21.8%
  • EPS has beaten the estimate in 7 of the most recent reported quarters.
  • Revenue surprise across the last 8 reported quarters has ranged from -3.5% to 11.4%.

Reported figures against analyst estimates, compiled from AlgovestIQ data, in U.S. dollars. The company reports in another currency, so the article's figures differ.

Novo reported DKK 79.2B in Q3 adjusted sales, up 4% at constant exchange rates, as growth returned across both U.S. and International Operations. Adjusted operating profit rose 27% to DKK 32B, aided by a favorable comparison with last year’s transformation costs, while free cash flow exceeded DKK 28B.

The quarter points to an improving volume trajectory after sales declines in late 2025 and early 2026. However, the recovery remains uneven: International Operations are expanding more quickly, while U.S. growth is being constrained by lower realized prices, seasonal demand patterns and continued payer resistance to broad obesity-drug coverage.

Earnings Snapshot

MetricReportedChange
Adjusted salesDKK 79.2B+4% at CER
Adjusted operating profitDKK 32B+27% at CER
Free cash flowMore than DKK 28BNot stated
U.S. Operations sales growthNot stated+1% at CER
International Operations sales growthNot stated+8% at CER
EUCAN sales growthNot stated+18% at CER
Obesity sales growthNot stated+22% at CER
International obesity sales growthNot stated+24% at CER
International GLP-1 sales growthNot stated+8% at CER
Patients treated across diabetes and obesityAround 48M+2M year over year
Patients treated for obesity5.6MNearly doubled year over year
Q3 patient additions1.3MVersus 1.2M in Q2
One-time Q3 costsAround DKK 3.5BRecognized in other operating expenses and R&D

The Bigger Story

Novo’s central investment development is the return to patient-volume growth after a period of contraction in early 2026. Management said the company added 1.3 million patients during Q3, following 1.2 million additions in Q2. That follows a loss of 0.8 million diabetes patients in Q1 and a flat-to-declining patient base at the end of 2025.

The improvement was broad enough to lift both operating units into growth territory. U.S. Operations grew 1%, while International Operations grew 8%, led by EUCAN’s 18% growth. Obesity remained the principal driver, but management also pointed to renewed diabetes patient additions as evidence that the recovery is extending beyond Wegovy.

The question for investors is whether this volume recovery can offset continued price pressure, particularly in the U.S. Novo expects lower realized U.S. prices from market-access investments and its most-favored-nation agreement. The company’s outlook still assumes a sales decline in U.S. Operations for the full year, even after its latest guidance increase.

Revenue and Operating Performance

Adjusted sales increased 4% at constant exchange rates to DKK 79.2B. The growth rate was slower than the 7% recorded in Q2 but marked the second consecutive quarter of expansion after adjusted sales fell 2% in Q4 2025 and 4% in Q1 2026.

Obesity sales increased 22% in Q3, supported by GLP-1 volume growth across geographies and the rollout of Wegovy pill and Wegovy 7.2 mg, or Wegovy HD. Novo said obesity treatments now reach 5.6 million people, nearly twice the level of a year earlier.

International Operations were the stronger contributor. Total International GLP-1 sales rose 8%, while obesity sales increased 24%. EUCAN was the largest growth region, with 18% growth, and Novo retained a 54% share of GLP-1 volumes across International Operations.

Canada was a notable offset. Management said lower realized prices after semaglutide lost exclusivity weighed on performance there. This is an early example of the broader loss-of-exclusivity pressure the company expects to become more meaningful in 2027, including in China.

In the U.S., Wegovy pill volumes rose about 20% sequentially in Q3, while injectable Wegovy volumes increased about 10%. Wegovy pill accounted for roughly 80% of new-to-brand oral obesity prescriptions, according to management, and had generated more than 8 million cumulative prescriptions since launch.

However, the quality of U.S. volume growth deserves scrutiny. Management said the Medicare Bridge program was a major, though not exclusive, contributor to the pill’s sequential growth. Excluding the Bridge program, the broader obesity-drug category was relatively flat from May through October, reflecting seasonal demand patterns. The program was generating about 60,000 total prescriptions per week across injectable and oral products at the latest reported point.

Novo also completed the transition from Rybelsus to Ozempic pill in the U.S. Weekly new-to-brand prescriptions for the oral diabetes franchise have more than doubled since launch, and management said more than 60% of Ozempic pill new-to-brand prescriptions came from patients who were new to GLP-1 treatment. That suggests the rebranding is expanding the treated market rather than only shifting patients between products.

Profitability and Margins

Adjusted operating profit increased 27% at constant exchange rates to DKK 32B. The year-over-year comparison benefited from approximately DKK 9B of company-wide transformation costs recognized in Q3 2025.

The quarter also included around DKK 3.5B of one-time costs in other operating expenses and R&D. Those costs partially offset the profit contribution from higher GLP-1 sales growth and demonstrate that the year-over-year operating-profit increase should not be treated solely as an underlying margin expansion measure.

Management said its updated outlook incorporates targeted spending on current and future growth opportunities in R&D and commercial activities. These investments are expected to be partly funded by savings from the transformation program started in 2025, further optimization efforts and disciplined resource allocation.

Demand, Customers and Pricing

Early Wegovy pill launches outside the U.S. have shown strong initial uptake. The product had launched in seven International Operations markets by Q3, including Mexico, France, Spain and Poland. Novo now expects Wegovy pill to be available in more than 20 markets by the first half of 2027, earlier than its previous expectation.

In the U.K., Wegovy pill held around 90% of the oral obesity market in recent weeks despite a competing launch. Weekly sales were approximately 60,000 packs, compared with 65,000 packs cited at the company’s Capital Markets Day. Management characterized this as a normalization after an early surge driven by pent-up demand, rather than a deterioration in the product’s competitive position.

Germany showed early evidence of market expansion, with around 100,000 Wegovy pill packs sold in the first six weeks after launch. Management said uptake was primarily from GLP-1-naive patients. In the UAE, Wegovy pill held around 80% of the oral obesity segment in recent weeks.

Wegovy HD is also becoming a more meaningful part of the obesity franchise. It represented approximately 5% of total U.S. Wegovy prescriptions, or around 20,000 prescriptions per week. Management said 80% of Wegovy HD use came from patients titrating up from Wegovy 2.4 mg, suggesting the higher dose has helped retain patients within the franchise who may otherwise have discontinued or switched.

Pricing remains the principal counterweight to volume growth in the U.S. Management indicated that Ozempic’s annual price erosion is still best viewed as 10% to 15%, despite more favorable pricing in Q3. For Wegovy, management cited price erosion of roughly 30% to 35% during the quarter and expects that level, or somewhat better, going forward.

Novo also expects U.S. list prices to decline on January 1, 2027. Management does not expect Medicare’s maximum fair price framework to create an additional negative effect on Ozempic beyond the pricing trajectory already assumed.

What is Novo’s guidance for 2026?

Novo raised its 2026 outlook for a second time.

Management now expects:

Metric2026 Guidance
Adjusted sales growth at CER-2% to +2%
Adjusted operating profit growth at CER-2% to +2%
Free cash flowDKK 60B to DKK 70B

The improved sales outlook is primarily based on higher expectations for GLP-1 product sales. Management expects growth in International Operations but a sales decline in U.S. Operations for the full year.

For the U.S., the outlook assumes continued prescription growth for injectable GLP-1 products but lower realized prices due to market-access investments and the most-favored-nation agreement. It also incorporates a range of assumptions for Wegovy pill uptake.

The implied Q4 outcome remains subject to meaningful variability. Management highlighted a difficult comparison from DKK 3B of favorable U.S. gross-to-net dynamics in Q4 2025, alongside a larger expected impact from Canadian loss of exclusivity.

Looking toward 2027, management did not provide formal guidance but identified both offsets and growth drivers. Potential positives include continued Wegovy pill uptake, annualization of the U.S. Bridge program and anticipated launches of CagriSema and Frehemgo, subject to approval. Risks include broader international loss of exclusivity, continued weakness in China and the possible reversal of favorable gross-to-net trends.

Balance Sheet, Cash Flow and Capital

Novo generated more than DKK 28B in Q3 free cash flow and lifted its full-year free-cash-flow outlook to DKK 60B to DKK 70B.

The company also announced that CFO Karsten Munk Knudsen will leave at the end of 2026 after 27 years with Novo. Luigi La Corte, formerly CFO of Galderma, will succeed him. Knudsen will remain through year-end to support the transition.

What Investors Should Watch

1. U.S. Growth Beyond the Bridge Program

The Bridge program helped drive Wegovy volume growth in Q3, but management acknowledged that the broader obesity-drug category was relatively flat from May through October without that contribution. Investors should monitor whether commercial coverage, consumer demand and the year-end wellness season create more durable growth beyond this temporary access initiative.

2. U.S. Net Pricing and Reimbursement

Novo is gaining patients but faces persistent net-price pressure in both diabetes and obesity. The ability to expand access without giving up additional pricing will determine whether higher volumes can translate into sustained revenue growth in the U.S.

3. International Wegovy Pill Conversion

The oral obesity launch has produced early signs of market expansion, particularly in Germany, and strong shares in the U.K. and UAE. The next test is whether initial demand converts into durable subscriptions, retention and broader patient penetration as launches extend to more than 20 markets.

4. CagriSema’s Launch Positioning

CagriSema could broaden Novo’s obesity portfolio beyond semaglutide alone. In a Type 2 diabetes study, the 1 mg/1 mg dose produced 12.4% weight loss versus 9.1% for tirzepatide 5 mg over 60 weeks, while delivering non-inferior HbA1c reduction of around 1.7 percentage points. Commercial uptake will depend on approval timing, reimbursement and whether the product’s efficacy profile can support differentiated positioning.

5. Loss of Exclusivity and China

Management expects international loss-of-exclusivity effects to increase in 2027, including in China, where sales were already down 2%. These pressures could offset some of the contribution from new product launches and pill-market expansion.

AlgovestIQ Takeaway

Novo’s Q3 results support management’s view that the business has moved into a recovery phase. Patient additions have resumed across obesity and diabetes, International Operations returned to stronger growth, and the Wegovy franchise is expanding through oral and higher-dose formulations rather than relying only on the established injectable product.

The stronger operating-profit growth should be interpreted carefully. It reflects higher GLP-1 sales, but it also benefited substantially from an easier comparison against DKK 9B of transformation costs last year. Novo also incurred DKK 3.5B of one-time costs in Q3, underscoring that quarterly profit growth is not a clean measure of underlying operating leverage.

The central unresolved issue remains the U.S. market. Novo’s prescription trends are improving, but Bridge-program volumes were a significant contributor, while the underlying category was seasonally flat outside that support. At the same time, payer concerns are shifting from unit price to total treatment volume, limiting the likelihood that lower prices alone will unlock broad commercial reimbursement.

International growth and the accelerated Wegovy pill rollout provide a meaningful counterbalance. Yet loss of exclusivity in markets such as Canada and China will increasingly matter, particularly as Novo enters 2027 with a more complicated price and competitive backdrop.

The investment case now rests on whether Novo can convert rising patient volumes and new-product launches into sustainable sales growth despite lower net pricing and international generic pressure. Evidence of broader U.S. access, durable oral-product retention and a differentiated CagriSema launch would strengthen that case. Continued reliance on temporary access programs or a faster-than-expected pricing deterioration would weaken it.

How did NVO stock react?

NVO closed at $42.18 on Nov 4, 2026, up 5.0% from $40.19 on Nov 3, 2026, the last close before the results were released.

SessionCloseChange
Nov 3, 2026 (before release)$40.19—
Nov 4, 2026$42.18+5.0%
Nov 5, 2026$40.30+0.3%

Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.

More from this earnings season

References

  1. Reported results, segment revenue, margins, cash flow and guidance quoted in this article. Source: Novo Nordisk A/S Q3 FY2026 earnings call transcript, as of Nov 4, 2026.
  2. Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Nov 4, 2026.

AI-generated analysis based on company-reported earnings data and earnings-call materials. Not investment advice.